Drugs With Tirzepatide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
This Zepbound and Mounjaro Eye Side Effect NAION Information Page provides some important evidence regarding an increased risk of non-arteritic ischemic optic neuropathy, or NAION, associated with these two tirzepatide-containing drugs.
The FDA has been investigating “potential signals” of the eye side effect NAION with Mounjaro and Zepbound — the active ingredient is tirzepatide for both medications — as well as other glucagon-like peptide-1 (GLP-1) receptor agonist drugs, collectively referred to as GLP-1 RAs. To learn more about how Zepbound and Mounjaro might be associated with the eye side effect NAION, you can read our June 2025 Drug Injury Watch blog post, “Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs”.
An August 2025 JAMA Network Open article, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“, provided more evidence for an increased risk of non-arteritic ischemic optic neuropathy, or NAION, with Ozempic (semaglutide) or Mounjaro (tirzepatide) in diabetes patients.
Here are some of the facts presented in that August 2025 medical article regarding the Mounjaro eye side effect NAION, specifically in diabetes patients:
- Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by loss of vision due to decreased blood flow to the optic nerve.
- The medical researchers compared Mounjaro (tirzepatide) with other antidiabetic medications for the associated risk of NAION in patients with type 2 diabetes who had no prior diagnosis of any eye disorder.
- Mounjaro (tirzepatide) is a newer and more potent GLP-RA to treat type 2 diabetes and obesity.
- In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that when Mounjaro (tirzepatide) was compared with other antidiabetic medications, there was an increased risk of NAION.
Besides Mounjaro, as we stated earlier, there is a second GLP-1RA drug that contains the active ingredient tirzepatide, Zepbound. That medication is used for obesity and weight loss purposes. There is some evidence that the NAION eye side effect may be associated with Zepbound, given that both drugs have the active ingredient tirzepatide.
Of course, we will continue to monitor relevant medical journals for additional studies concerning the association of NAION with Mounjaro and Zepbound. Further, we await the outcome of that FDA investigation into the eye side effect NAION with Mounjaro and Zepbound.
Free Case Evaluation for Zepbound or Mounjaro Eye Side Effect NAION
We encourage you to submit a Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Zepbound or Mounjaro drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Articles About Zepbound and Mounjaro Eye Side Effect NAION With Vision Loss
NAION Cases Filed in Courts for Vision Loss Legal Compensation
We are handling NAION cases filed in courts around the country to help people obtain legal compensation for vision loss.
People using Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound who seek legal compensation for vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) have filed more than 200 lawsuits as of August 2026.
To read more of this article, click below:
In December 2025, all the federal NAION cases filed in courts were consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML). This JPML ruling appointed U.S. District Judge Karen S. Marston, in the Eastern District of Pennsylvania, to preside over this consolidated federal court NAION litigation: MDL-3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation.
There are additional NAION cases filed in courts around the country on behalf of people seeking legal compensation for vision loss. Those NAION lawsuits are pending in numerous different state courts.
The NAION vision loss cases in each of those courts involve, for the most part, these popular drugs used for diabetes or weight loss: Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound.
We have been reporting on the medical and legal developments pertinent to these NAION cases filed in courts for more than two years, since July 2024.
Here is a list of some past relevant Drug Injury Law articles you may want to read for background information:
- Ozempic Eye Side Effect NAION Warnings Update July 2026
- Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss
- NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
More vision loss cases are being investigated, so there will be more NAION cases filed in courts during 2026 and the next couple of years.
People diagnosed with NAION who suffered vision loss while using Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound can submit an online Case Evaluation Form to be reviewed by drug injury lawyer Tom Lamb:
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound vision-loss legal compensation case involving NAION.
[Read the article in full at source]Earlier articles about eye-related side effects of Mounjaro and Zepbound:
- NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound